Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levodopa/carbidopa/entacapone - Orion/Novartis

Drug Profile

Levodopa/carbidopa/entacapone - Orion/Novartis

Alternative Names: Carbidopa/entacapone/levodopa; ELC-200; Entacapone/levodopa/carbidopa; Stalevo; Stavelo

Latest Information Update: 12 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orion
  • Developer Novartis; Orion
  • Class Antiparkinsonians; Catecholamines; Catechols; Hydrazines; Nitriles; Small molecules
  • Mechanism of Action Catechol O-methyltransferase inhibitors; Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 12 Feb 2019 Chemical structure information added
  • 03 Dec 2018 Novartis returns sales and marketing rights for Levodopa/carbidopa/entacapone for Parkinson's disease to Orion, in 18 European Union countries and certain countries outside European Union
  • 16 Feb 2017 Eisai acquires marketing rights for levodopa/carbidopa/entacapone from Orion Pharma in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top